Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15688572 | 0.79 | LMNA (0.39) | LMNAKDM4EALDH1A1BRD4IDO1 | |
| SCHEMBL29237933 | 0.74 | ALDH1A1 (0.34) | LMNAKDM4EALDH1A1 | |
| SCHEMBL3668788 | 0.73 | LMNA (0.48) | LMNAKDM4EALDH1A1IDO1 | |
| SCHEMBL24575348 | 0.72 | — | — | |
| SCHEMBL15866079 | 0.69 | — | — | |
| SCHEMBL11630670 | 0.67 | LMNA (0.41) | LMNAKDM4EALDH1A1IDO1 | |
| SCHEMBL12986501 | 0.65 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL20869795 | 0.65 | LMNA (0.39) | LMNAKDM4EALDH1A1IDO1 | |
| SCHEMBL2067816 | 0.65 | LMNA (0.46) | LMNAKDM4EALDH1A1IDO1 | |
| SCHEMBL13822465 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023125619-A1 | ANTI-ROR1 ANTIBODY, AND ANTI-ROR1 ANTIBODY-DRUG CONJUGATE AND MEDICAL USES THEREOF | 江苏恒瑞医药股份有限公司 | 2023-07-06 | — | — | WO | disclosed |
| WO-2022166799-A1 | FUSED TRICYCLIC CYCLIN-DEPENDENT KINASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 上海拓界生物医药科技有限公司 | 2022-08-11 | — | — | WO | disclosed |
| CN-105566321-B | Heteroaromatic compounds and their use in medicine | 广东东阳光药业有限公司 | 2020-04-21 | — | — | CN | disclosed |
| EP-2944637-B1 | NITROGEN-CONTAINING HETEROCYLIC COMPOUND OR SALT THEREOF | FUJIFILM CORP (JP) | 2020-02-19 | — | — | EP | disclosed |
| US-9783536-B2 | Nitrogen-containing heterocyclic compound or salt thereof | FUJIFILM CORPORATION (JP) | 2017-10-10 | — | — | US | disclosed |
| CN-105566321-A | Heterarylation compound and application thereof to drugs | GUANGDONG HEC PHARMACEUTICAL | 2016-05-11 | — | — | CN | disclosed |
| EP-2944637-A1 | NITROGEN-CONTAINING HETEROCYLIC COMPOUND OR SALT THEREOF | FUJIFILM Corporation (JP) | 2015-11-18 | — | — | EP | disclosed |
| US-20150322063-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2015-11-12 | — | — | US | disclosed |
| CN-104903320-A | Nitrogen-containing heterocylic compound or salt thereof | FUJIFILM CORP | 2015-09-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322063-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | NPM1, NAP1L1, REN | LMNA 1700/4885KDM4E 3197/4885ALDH1A1 1595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.